Polymyalgia rheumatic
10 Salvarani C, Macchioni P, Manzini C, et al . Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007;146:631–9. 11 Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther 2010;12:R176. 12 De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136–8. 13 Matteson EL, Buttgereit F, Dejaco C, et al . Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2016;42:75–90. viii. 14 Buttgereit F, Matteson EL, Dejaco C. Polymyalgia rheumatica and giant cell arteritis. JAMA 2020;324:993–4. 15 Roche NE, Fulbright JW, Wagner AD, et al . Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286–94. 16 Alvarez-Rodríguez L, Lopez-Hoyos M, Mata C, et al . Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 2010;69:263–9. 17 Izumi K, Kuda H, Ushikubo M, et al . Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open 2015;1:e000162. 18 Chino K, Kondo T, Sakai R, et al . Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Rheum Dis 2019;22:2151–7. 19 Devauchelle-Pensec V, Berthelot JM, Cornec D, et al . Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 2016;75:1506–10. 20 Lally L, Forbess L, Hatzis C, et al . Brief report: a prospective open-label phase IIA trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 2016;68:2550–4.
21 Dasgupta B, Cimmino MA, Maradit-Kremers H. Provisional classification criteria for polymyalgia rheumatica: a European League against Rheumatism/American College of rheumatology collaborative initiative. Ann Rheum Dis 2012;2012:484–92. 22 Mackie SL, Twohig H, Neill LM, et al . The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica. J Rheumatol 2017;44:1515–21. 23 Dejaco C, Duftner C, Cimmino MA, et al . Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011;70:447–53. 24 Binard A, De Bandt M, Berthelot J-M, et al . Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum 2007;57:481–6. 25 Stone JH, Tuckwell K, Dimonaco S, et al . Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28. 26 Mazzantini M, Torre C, Miccoli M, et al . Adverse events during longterm low- dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012;39:552–7. 27 Dejaco C, Singh YP, Perel P, et al . Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review Informing the 2015 European League against Rheumatism/American College of rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 2015;74:1808–17. 28 Saag KG, Koehnke R, Caldwell JR, et al . Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115–23. 29 Pers Y-M, Schaub R, Constant E, et al . Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine 2015;82:25–30. 30 Ebina K, Hashimoto M, Yamamoto W, et al . Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The answer cohort study. PLoS One 2019;14:e0216624.
Bonelli M, et al . Ann Rheum Dis 2022; 81 :838–844. doi:10.1136/annrheumdis-2021-221126
844
Powered by FlippingBook